A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
Han SiMichael KuzioraKatie J QuinnElena HelmanJiabu YeFeng LiuUrban ScheuringSolange PetersNaiyer A RizviPhilip Z BrohawnKoustubh RanadeBrandon W HiggsKimberly C BanksVikram K ChandRajiv RajaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our study demonstrates the feasibility, accuracy, and reproducibility of the GuardantOMNI ctDNA platform for quantifying bTMB from plasma samples. Using the new bTMB algorithm and an optimal bTMB cutoff of ≥20 mut/Mb, high bTMB was predictive of clinical benefit with durvalumab + tremelimumab versus chemotherapy.